Literature DB >> 18695000

PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Hee-Jun Wee1, Dominic Chih-Cheng Voon, Suk-Chul Bae, Yoshiaki Ito.   

Abstract

The heterodimeric transcription factor RUNX1/PEBP2-beta (also known as AML1/CBF-beta) is essential for definitive hematopoiesis. Here, we show that interaction with PEBP2-beta leads to the phosphorylation of RUNX1, which in turn induces p300 phosphorylation. This is mediated by homeodomain interacting kinase 2 (HIPK2), targeting Ser(249), Ser(273), and Thr(276) in RUNX1, in a manner that is also dependent on the RUNX1 PY motif. Importantly, we observed the in vitro disruption of this phosphorylation cascade by multiple leukemogenic genetic defects targeting RUNX1/CBFB. In particular, the oncogenic protein PEBP2-beta-SMMHC prevents RUNX1/p300 phosphorylation by sequestering HIPK2 to mislocalized RUNX1/beta-SMMHC complexes. Therefore, phosphorylation of RUNX1 appears a critical step in its association with and phosphorylation of p300, and its disruption may be a common theme in RUNX1-associated leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695000      PMCID: PMC2572802          DOI: 10.1182/blood-2008-01-134122

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.

Authors:  M S Petrovick; S W Hiebert; A D Friedman; C J Hetherington; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

2.  Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Authors:  Y Kanno; T Kanno; C Sakakura; S C Bae; Y Ito
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells.

Authors:  Y W Zhang; S C Bae; G Huang; Y X Fu; J Lu; M Y Ahn; Y Kanno; T Kanno; Y Ito
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.

Authors:  I Kitabayashi; A Yokoyama; K Shimizu; M Ohki
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

5.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

Authors:  D A Yergeau; C J Hetherington; Q Wang; P Zhang; A H Sharpe; M Binder; M Marín-Padilla; D G Tenen; N A Speck; D E Zhang
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

Review 6.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

7.  Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult.

Authors:  Lena Motoda; Motomi Osato; Namiko Yamashita; Bindya Jacob; Lynnette Q Chen; Masatoshi Yanagida; Hiroshi Ida; Hee-Jun Wee; Alfred X Sun; Ichiro Taniuchi; Dan Littman; Yoshiaki Ito
Journal:  Stem Cells       Date:  2007-09-06       Impact factor: 6.277

8.  Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases.

Authors:  W Becker; Y Weber; K Wetzel; K Eirmbter; F J Tejedor; H G Joost
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.

Authors:  N Adya; T Stacy; N A Speck; P P Liu
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors.

Authors:  D Levanon; R E Goldstein; Y Bernstein; H Tang; D Goldenberg; S Stifani; Z Paroush; Y Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  28 in total

1.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 2.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Runx2 trans-activation mediated by the MSX2-interacting nuclear target requires homeodomain interacting protein kinase-3.

Authors:  Oscar L Sierra; Dwight A Towler
Journal:  Mol Endocrinol       Date:  2010-05-19

4.  DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.

Authors:  Shanshan Li; Chu Xu; Yinkun Fu; Pin-Ji Lei; Yanhua Yao; Wanli Yang; Ying Zhang; Michael P Washburn; Laurence Florens; Manish Jaiswal; Min Wu; Man Mohan
Journal:  Nucleic Acids Res       Date:  2018-11-30       Impact factor: 16.971

5.  Effects of Y361-auto-phosphorylation on structural plasticity of the HIPK2 kinase domain.

Authors:  Antonella Scaglione; Laura Monteonofrio; Giacomo Parisi; Cristina Cecchetti; Francesca Siepi; Cinzia Rinaldo; Alessandra Giorgi; Daniela Verzili; Carlotta Zamparelli; Carmelinda Savino; Silvia Soddu; Beatrice Vallone; Linda Celeste Montemiglio
Journal:  Protein Sci       Date:  2017-12-28       Impact factor: 6.725

Review 6.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 7.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 8.  Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.

Authors:  Vera V Saul; M Lienhard Schmitz
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

9.  Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271.

Authors:  Kensuke Sakamoto; Bo-Wen Huang; Kenta Iwasaki; Kiros Hailemariam; Jun Ninomiya-Tsuji; Yoshiaki Tsuji
Journal:  Mol Biol Cell       Date:  2010-06-23       Impact factor: 4.138

10.  HIPK2 modulates p53 activity towards pro-apoptotic transcription.

Authors:  Rosa Puca; Lavinia Nardinocchi; Ada Sacchi; Gideon Rechavi; David Givol; Gabriella D'Orazi
Journal:  Mol Cancer       Date:  2009-10-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.